Morgan Stanley Reiterates Underweight on Genmab, Maintains $33 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison reiterated an Underweight rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.
June 20, 2023 | 1:05 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley analyst Matthew Harrison reiterated an Underweight rating on Genmab (NASDAQ:GMAB) and maintained a $33 price target.
The Underweight rating by Morgan Stanley analyst Matthew Harrison suggests that Genmab's stock may underperform compared to other stocks in the market. The maintained $33 price target indicates that the analyst does not expect significant upside potential in the short term. This news is likely to have a negative impact on GMAB's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100